Bloom Speech Therapy, Llc | |
92 Senate Brook Dr, Amston, CT 06231-1521 | |
(860) 685-0819 | |
Not Available |
Full Name | Bloom Speech Therapy, Llc |
---|---|
Type | Facility |
Speciality | Speech-language Pathologist |
Location | 92 Senate Brook Dr, Amston, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1134715675 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Bloom Speech Therapy, Llc Po Box 852, Glastonbury, CT 06033-0852 Ph: () - | Bloom Speech Therapy, Llc 92 Senate Brook Dr, Amston, CT 06231-1521 Ph: (860) 685-0819 |
News Archive
Ludwig-Maximilians-Universitaet (LMU) in Munich researchers report that a central component of the innate immune response is activated by two short RNAs which are produced by site-specific cleavage of a precursor RNA molecule - and both derivatives are generated by the same enzyme.
Aelan Cell Technologies today announced they have entered into an agreement with the Gladstone Institutes to further its studies on stem cell rejuvenation. This effort will be led by Meenakshi Gaur, Ph.D. of Aelan Cell Technologies and Kathryn Ivey, Ph.D. of the Gladstone Institutes.
Pharmacists and drugstores appear to have undone an effort to impose more strict controls on drug controls. Meanwhile, Accretive Health, the Chicago-based hospital-billing company which is under fire, is fighting back.
With millions of students heading back to school, the childhood obesity crisis and nutrition legislation continues to top the agenda in Washington, the medical community, and for educators, parents and guardians across the country.
Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.
› Verified 4 days ago
Jocelyn Knight, M.A.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 Congress Dr, Amston, CT 06231 Phone: 860-531-8073 | |
Amston Speech-language Pathology, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 127 Congress Dr, Amston, CT 06231 Phone: 203-895-5650 |